3 Investor presentation First nine months of 2023 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), in February 2023 in continuation of the publication of this Annual Report 2022, this presentation, and wr Novo Nordisk, may contain forward- looking statements. Words such as ‘believe’, ‘expect, ‘may’, ‘will’, ‘p words and terms of similar meaning in connection with any discussion of future operating or financial include, but are not limited to: • Statements of targets, plans, objectives or goals for future operations, including those related to product approvals as well as cooperation in relation thereto, • Statements containing projections of or targets for revenues, costs, income (or loss), earnings pe measures, • Statements regarding future economic performance, future actions and outcome of contingencie • Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward Nordisk cautions that a number of important factors, including those described in this presentation, co statements. Factors that may affect future results include, but are not limited to, global as well as local political and of projects related to research and/or development, unplanned loss of patents, interruptions of suppli Novo Nordisk relies, shortages of supplies, including energy supplies, product recalls, unexpected con Nordisk’s products, introduction of competing products, reliance on information technology including products, exposure to product liability and legal proceedings and investigations, changes in governme protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or a and foreign companies, unexpected growth in costs and expenses, strikes and other labour market dis and epidemics, pandemics or other public health crises, and the effects of domestic or international cr For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or t overview of risk factors in ‘Risk management’ of this Annual Report 2022. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revi result of new information, future events, or otherwise. Important drug information Victoza ® and Ozempic ® are approved for the management of type 2 diabetes only Saxenda ® and Wegovy ® are approved for the treatment of obesity only
Download PDF file